Full View

Kinase domain point mutations in Philadelphia chromosome‐positive acute lymphoblastic leukemia emerge after therapy with BCR‐ABL kinase inhibitors

D Jones, D Thomas, CC Yin, S O'Brien, JE Cortes… - Cancer, 2008 - Wiley Online Library
Abstract BACKGROUND. BCR‐ABL kinase domain (KD) mutations are detected in
approximately 45% of patients with imatinib‐resistant chronic myeloid leukemia. Patterns of …
被引用次数：152 相关文章

[引用][C] Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors

D Jones - Cancere, 2008 - cir.nii.ac.jp
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic
leukemia emerge after therapy with BCR-ABL kinase inhibitors | CiNii Research CiNii 国立 …
[PDF] researchgate.net

[PDF][PDF] Kinase Domain Point Mutations in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Emerge After Therapy With BCR-ABL Kinase Inhibitors

D Jones, D Thomas, CC Yin, S O'Brien, JE Cortes… - CANCER, 2008 - researchgate.net
BACKGROUND. BCR-ABL kinase domain (KD) mutations are detected in approximately
45% of patients with imatinib-resistant chronic myeloid leukemia. Patterns of KD mutations in …

Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors

D Jones, D Thomas, CC Yin, S O'Brien… - Cancer, 2008 - pubmed.ncbi.nlm.nih.gov
Background BCR-ABL kinase domain (KD) mutations are detected in approximately 45% of
patients with imatinib-resistant chronic myeloid leukemia. Patterns of KD mutations in …

[引用][C] Kinase Domain Point Mutations in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Emerge After Therapy With BCR-ABL Kinase Inhibitors

D JONES, D THOMAS, CC YIN, S O'BRIEN… - Cancer, 2008 - pascal-francis.inist.fr
Kinase Domain Point Mutations in Philadelphia Chromosome-positive Acute Lymphoblastic
Leukemia Emerge After Therapy With BCR-ABL Kinase Inhibitors CNRS Inist Pascal-Francis …

Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.

D Jones, D Thomas, CC Yin, S O'Brien, JE Cortes… - Cancer, 2008 - europepmc.org
Background BCR-ABL kinase domain (KD) mutations are detected in approximately 45% of
patients with imatinib-resistant chronic myeloid leukemia. Patterns of KD mutations in …

Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors

D Jones, D Thomas, CC Yin, S O'Brien… - …, 2008 - scholars.northwestern.edu
BACKGROUND. BCR-ABL kinase domain (KD) mutations are detected in approximately
45% of patients with imatinib-resistant chronic myeloid leukemia. Patterns of KD mutations in …

Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors

D Jones, D Thomas, CC Yin, S O'Brien… - …, 2008 - mdanderson.elsevierpure.com
BACKGROUND. BCR-ABL kinase domain (KD) mutations are detected in approximately
45% of patients with imatinib-resistant chronic myeloid leukemia. Patterns of KD mutations in …

Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors

D Jones, D Thomas, CC Yin, S O'Brien… - …, 2008 - augusta.elsevierpure.com
BACKGROUND. BCR-ABL kinase domain (KD) mutations are detected in approximately
45% of patients with imatinib-resistant chronic myeloid leukemia. Patterns of KD mutations in …

Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors

D Jones, D Thomas, CC Yin, S O'Brien… - …, 2008 - ohiostate.elsevierpure.com
BACKGROUND. BCR-ABL kinase domain (KD) mutations are detected in approximately
45% of patients with imatinib-resistant chronic myeloid leukemia. Patterns of KD mutations in …